Pharma

Your Article Summary

See Latest Articles

FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)
GlaxoSmithKline, 06/02/09

GlaxoSmithKline and Genmab A/S announced that the United States Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10 to three that the ARZERRA data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia whose disease is refractory to fludarabine and alemtuzumab.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Multaq Approved in the European Union for Patients with Atrial Fibrillation
Sanofi-aventis, 12/01/09

FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09

FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
BioMarin, 12/01/09

 See all of Drug/Product Approvals